Pancreatic Cancer Clinical Trials in Arizona

Showing 41-60 of 134 trials

AOH1996 for the Treatment of Refractory Solid Tumors

NCT05227326

This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Refractory Malignant Solid NeoplasmOsteosarcomaLeiomyosarcomas+4 more

City of Hope Medical Center92 participantsStarted Aug 2022

Scottsdale, Arizona, United States • Duarte, California, United States

COMPLETEDPhase 231 miles

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

NCT02723331

The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in response to neoadjuvant sequential therapy of combination nab-paclitaxel and gemcitabine followed by stereotactic body radiotherapy (SBRT).

Pancreatic CancerPancreatic AdenocarcinomaPancreas Ductal Adenocarcinoma

Academic Thoracic Oncology Medical Investigators Consortium48 participantsStarted Dec 2016

Scottsdale, Arizona, United States • Tucson, Arizona, United States • Aurora, Colorado, United States +1 more locations

AOH1996 for the Treatment of Refractory Solid Tumors

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

Pancreatic Cancer Trials in Other Cities

L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

Milademetan in Advanced/Metastatic Solid Tumors

Other Conditions in Arizona